Latuda lurasidone: Updated Phase III data

Sumitomo said updated data from the double-blind, Asian Phase III PASTEL trial of lurasidone no longer support approval of the product to treat schizophrenia in Japan. In 439 patients in the modified

Read the full 326 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE